Given that several of these genetic variants have displayed associations with amyloid-positron emission tomography burden in prior studies (Ramanan et al., 2014, 2015; Apostolova et al., 2018), our findings suggest that the genetic background influencing tau pathology may meaningfully differ from the set of genes typically proposed as top loci for Alzheimer’s disease clinical diagnosis. Here, MAPT is linked to Alzheimer disease.